Tolcapone

Generic Name: Tolcapone

Brand Names: Tasmar

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₁NO_₅

CAS Number: 134308-13-7

Unique Ingredient Identifier: CIF6334OLY

Background: Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.

Indication: Used as an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of Parkinson's Disease. This drug is generally reserved for patients with parkinsonian syndrome receiving levodopa/carbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies.

Associated Conditions: Idiopathic Parkinson's Disease

Associated Therapies: -

Clinical Trials

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

Phase 1

Terminated

Conditions: Neuroblastoma

Interventions: Drug: Tolcapone
Drug: Oxaliplatin

First Posted Date: 2015-12-15

Last Posted Date: 2024-08-06

Lead Sponsor: Giselle Sholler

Target Recruit Count: 5

Registration Number: NCT02630043

Locations: 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
🇺🇸
Levine Children's Hospital, Charlotte, North Carolina, United States

and more 6 locations

Treatment for Nicotine Addiction in Women

Not Applicable

Completed

Conditions: Nicotine Dependence

Interventions: Drug: Sugar Pill
Drug: Tolcapone

First Posted Date: 2015-05-19

Last Posted Date: 2020-11-24

Lead Sponsor: Yale University

Target Recruit Count: 36

Registration Number: NCT02448654

Locations: 🇺🇸
Veterans Administration Hospital, West Haven, Connecticut, United States

Remediation of Impaired Self-Regulation in Patients With Mild TBI

Not Applicable

Completed

Conditions: Mild Traumatic Brain Injury

Interventions: Drug: Tolcapone
Drug: Placebo

First Posted Date: 2014-10-09

Last Posted Date: 2022-03-11

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 55

Registration Number: NCT02260570

Locations: 🇺🇸
VA Northern California Health Care System, Mather, CA, Sacramento, California, United States

Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tolcapone
Drug: Placebo

First Posted Date: 2014-03-06

Last Posted Date: 2014-09-12

Lead Sponsor: University of Zurich

Target Recruit Count: 30

Registration Number: NCT02080715

Locations: 🇨🇭
University of Zurich, Institute of Pharmacology and Toxicology, Zurich, Switzerland

Pilot Study of Tolcapone in Smokers

Phase 2

Completed

Conditions: Nicotine Dependence

Interventions: Drug: Placebo
Drug: Tolcapone

First Posted Date: 2010-09-16

Last Posted Date: 2018-09-12

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 19

Registration Number: NCT01202955

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors

Not Applicable

Completed

Conditions: Impulsive Behavior

Interventions: Other: Placebo
Drug: Tolcapone

First Posted Date: 2010-07-08

Last Posted Date: 2020-11-20

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 26

Registration Number: NCT01158950

Locations: 🇺🇸
UCSF: Ernest Gallo Clinic and Research Center, Emeryville, California, United States
🇺🇸
University of California, Berkeley, Berkeley, California, United States

Neural Substrates in Nicotine Withdrawal

Phase 2

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: Placebo
Drug: Tolcapone

First Posted Date: 2009-10-26

Last Posted Date: 2014-07-02

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 218

Registration Number: NCT01001520

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Tolcapone Treatment of Pathological Gambling

Phase 2

Completed

Conditions: Pathological Gambling

Interventions: Drug: Tolcapone

First Posted Date: 2009-06-25

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 24

Registration Number: NCT00927563

Locations: 🇺🇸
Ambulatory Research Center, Minneapolis, Minnesota, United States

Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors

Phase 4

Completed

Conditions: Parkinson Disease

Interventions: Drug: levodopa/carbidopa
Drug: entacapone
Drug: tolcapone

First Posted Date: 2009-05-21

Last Posted Date: 2010-01-18

Lead Sponsor: Uppsala University

Target Recruit Count: 10

Registration Number: NCT00906828

Locations: 🇸🇪
Uppsala University Hospital, Uppsala, Sweden

Effects of Tolcapone on Frontotemporal Dementia

Phase 2

Completed

Conditions: Frontotemporal Lobar Degeneration

Interventions: Drug: Tolcapone
Drug: Placebo

First Posted Date: 2008-01-30

Last Posted Date: 2024-08-28

Lead Sponsor: Columbia University

Target Recruit Count: 28

Registration Number: NCT00604591

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy